27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Calithera Biosciences Inc (NASDAQ:CALA) shares were making a strong upward move Monday following a clinical trial readout from the company.
What Happened
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Calithera, which develops novel small molecule therapies for cancer and other life-threatening diseases, announced positive top-line results from a Phase 2 study dubbed ENTRATA that is evaluating telaglenastat, or CB-839, in combination with the chemotherapy drug everolimus in patients with renal cell carcinoma.
Telaglenastat is the first glutaminase inhibitor to demonstrate clinical activity for treating cancer.
The enrolled patients were heavily pre-treated with a median of three prior lines of therapy for advanced metastatic disease, including immunotherapy and multiple tyrosine kinase inhibitors.
The enrollees demonstrated that the evaluated combo treatment doubled the median progress-free survival to 3.8 months compared to 1.9 months for everolimus alone, Calithera said.
The risk of disease progression or death was also reduced by 36% in the combo treatment arm.
The combination was well-tolerated.
Want Private Access to Benzinga Analyst?
Check out the latest strategies our team of experts are using every week so that you can always adapt to the market like the pros!—Get FULL Access to This Week's Webinar Here.
The secondary endpoint of overall survival has yet to mature, according to the South San Francisco, California-based biotech.
Why It's Important
Telaglenastat is Calithera's lead product candidate and is being evaluated in several combinations for renal cell carcinoma as well as solid tumors.
Two separate trials for renal cell carcinoma in combination with the chemotherapy drug cabozantinib and with everolimus are in the most advanced stage of clinical development among its pipeline assets.
"The achievement of positive topline results in our first randomized trial is a significant milestone for Calithera because it provides clinical proof of concept for teleglenastat," Calithera CEO Susan Molineaux said in a statement.
Calithera shares were up 3.84% at $5.41 at the time of publication Monday.
Related Links:
The Week Ahead In Biotech: Conferences, PDUFA Dates Clinical Trial Readouts And IPOs
Enanta's Respiratory Virus Drug Aces Midstage Study
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.